S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
MENLO PARK, CA – Joshua J. Ofman, President of Grail , Inc. (NASDAQ:GRAL), recently executed a sale of common stock, according to a filing with the Securities and Exchange Commission. The transaction comes as the stock has experienced significant volatility, with a -20% decline over the past week despite an impressive 125% gain over the last six months. On March 7, Ofman sold 2,109 shares of Grail stock at a weighted average price of $31.20 per share, amounting to a total transaction value of $65,800.
Following this transaction, Ofman’s direct ownership stands at 559,673 shares. The sale was part of a block trade executed in multiple transactions, as detailed in the filing.
In other recent news, Grail Inc. reported a 26% increase in revenue for the fourth quarter of 2024, totaling $38.3 million. This growth was part of a broader trend, with the company’s annual revenue for 2024 rising by 35% to $125.6 million. Despite a net loss of $97.1 million in the quarter, Grail managed to reduce its quarterly loss by 48%. The company also launched an enhanced version of its Galleri test, which contributed to the sale of 137,000 tests throughout the year. Grail maintained its 2025 guidance, projecting a reduction in cash burn to no more than $320 million. The company plans to complete its registrational studies and submit a modular PMA to the FDA by the first half of 2026. Additionally, Grail’s Galleri test was added to the U.S. Military’s TRICARE health insurance program as a covered benefit for eligible patients. These developments reflect Grail’s strategic advancements in product development and market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.